title: Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
abstract: We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatment, such as aggressive posterior ROP or poor mydriasis. 2 eyes of 1 infant received intravitreal ranibizumab alone and 8 eyes of 5 infants received combined intravitreal ranibizumab and laser therapy. 3 out of 8 eyes treated initially with intravitreal ranibizumab monotherapy had persistent disease requiring laser therapy, and 3 out of 5 eyes with initial regression suffered disease recurrence at a mean of 7.6 weeks post-injection. 2 eyes treated first with laser followed by intravitreal ranibizumab had disease regression without recurrence. Our cohort demonstrate a significant rate of persistent disease and recurrence in ROP eyes treated initially with intravitreal ranibizumab monotherapy, which is greater and earlier than that reported for intravitreal bevacizumab in the BEAT-ROP study. Intravitreal ranibizumab may be useful as an initial treatment in selected cases of ROP when laser therapy as first line is suboptimal. However, close monitoring is important and adjunctive laser therapy may subsequently be needed in a majority of cases.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Joyce J T
authors.initials: JJT
authors.lastname: Chan
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Carol P S
authors.initials: CPS
authors.lastname: Lam
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Madeline K M
authors.initials: MKM
authors.lastname: Kwok
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Raymond L M
authors.initials: RLM
authors.lastname: Wong
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Gary K Y
authors.initials: GKY
authors.lastname: Lee
authors.affiliation: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Winnie W Y
authors.initials: WWY
authors.lastname: Lau
authors.affiliation: Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K, Argyle Street, Kowloon City, Kowloon, Hong Kong SAR.
authors.forename: Jason C S
authors.initials: JCS
authors.lastname: Yam
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use*; D012008:Recurrence; D012160:Retina / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D000069579:Ranibizumab